Cormorant Capital

Cormorant Capital

Cormorant Capital

06 Jan 2019
$50,000,000
Venture capital (Series B)

Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies

MedCity News
+1
13 Sep 2017